Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Breast Diseases 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Thrombocythemia, Essential 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Polycythemia Vera 1Ovarian Neoplasms 1Lymphedema 1Liver Neoplasms 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hypogonadism 1Glioma 1Gastric Adenocarcinoma 1Fatigue Syndrome, Chronic 1Eunuchism 1Colonic Neoplasms 1Amyloidosis 1Adenoma 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Drug Evaluation × Clear all
NCT07532148 2026-04-15

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Chong Kun Dang Pharmaceutical

Phase 1 Not yet recruiting
24 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡